pyrazines has been researched along with Psoriasis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Chen, X; Jiang, R; Liu, J; Wang, Y; Xu, J; Yin, M; Zhang, Y | 1 |
| Braiteh, F; Giralt, SA; Hymes, SR; Jones, R | 1 |
| Cheung, PH; Foreman, O; Hain, HS; Kaur, P; Kavirayani, A; Saha, S; Tung, D | 1 |
| Hashimoto, K; Kumagai, C; Nishioka, T; Shinohara, M; Tanimoto, N | 1 |
| Caminal-Montero, L; Coto-Segura, P; Esteve-Martinez, A; Mas-Vidal, A; Santos-Juanes, J | 1 |
| Boehncke, WH; Elliott, PJ; Zollner, TM | 1 |
1 review(s) available for pyrazines and Psoriasis
| Article | Year |
|---|---|
Proteasome inhibition: a new anti-inflammatory strategy.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis, Rheumatoid; Asthma; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Disease Models, Animal; Humans; Inflammation; Lysine; Models, Biological; Models, Chemical; Multienzyme Complexes; Multiple Sclerosis; Neoplasms; NF-kappa B; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Psoriasis; Pyrazines; Reperfusion Injury | 2003 |
5 other study(ies) available for pyrazines and Psoriasis
| Article | Year |
|---|---|
Ligustrazine alleviates psoriasis-like inflammation through inhibiting TRAF6/c-JUN/NFκB signaling pathway in keratinocyte.
Topics: Inflammation; Keratinocytes; Ligusticum; NF-kappa B; Psoriasis; Pyrazines; Signal Transduction; TNF Receptor-Associated Factor 6 | 2022 |
Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Psoriasis; Pyrazines; Remission Induction | 2008 |
Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dinitrofluorobenzene; Disease Models, Animal; Drug Compounding; Drug Evaluation, Preclinical; Drug Stability; Female; Hypersensitivity, Delayed; Imiquimod; Immunologic Factors; Irritants; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Peritonitis; Psoriasis; Pyrazines; Random Allocation; Temperature; Thioglycolates | 2011 |
Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Psoriasis; Pyrazines; Sitagliptin Phosphate; T-Lymphocytes; Treatment Outcome; Triazoles | 2012 |
Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Extremities; Female; Humans; Middle Aged; Psoriasis; Pyrazines; Sitagliptin Phosphate; Torso; Triazoles | 2012 |